138 related articles for article (PubMed ID: 33359446)
1. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo M; Dai S; Wu D; Duan Y; Li J; Qu L; Jiang L; Chen Z; Chen X; Chen Y
Bioorg Med Chem Lett; 2021 Feb; 34():127757. PubMed ID: 33359446
[TBL] [Abstract][Full Text] [Related]
2. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
3. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
[TBL] [Abstract][Full Text] [Related]
4. Chemical genetic strategy for targeting protein kinases based on covalent complementarity.
Garske AL; Peters U; Cortesi AT; Perez JL; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15046-52. PubMed ID: 21852571
[TBL] [Abstract][Full Text] [Related]
5. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Ye Z; Wang Y; Wu H; Song T; Li X; Liu Q; Wang C
Chembiochem; 2021 Jan; 22(1):129-133. PubMed ID: 32979005
[TBL] [Abstract][Full Text] [Related]
6. Structural study of ponatinib in inhibiting SRC kinase.
Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
8. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
[TBL] [Abstract][Full Text] [Related]
9. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
10. Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib.
Barragan AM; Ghaby K; Pond MP; Roux B
J Chem Inf Model; 2024 Apr; 64(8):3488-3502. PubMed ID: 38546820
[TBL] [Abstract][Full Text] [Related]
11. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
12. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles.
Georghiou G; Kleiner RE; Pulkoski-Gross M; Liu DR; Seeliger MA
Nat Chem Biol; 2012 Feb; 8(4):366-74. PubMed ID: 22344177
[TBL] [Abstract][Full Text] [Related]
13. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
Kwarcinski FE; Fox CC; Steffey ME; Soellner MB
ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
[TBL] [Abstract][Full Text] [Related]
15. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
17. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
18. Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.
Balıkçı E; Marques AMC; Bauer LG; Seupel R; Bennett J; Raux B; Buchan K; Simelis K; Singh U; Rogers C; Ward J; Cheng C; Szommer T; Schützenhofer K; Elkins JM; Sloman DL; Ahel I; Fedorov O; Brennan PE; Huber KVM
J Med Chem; 2024 May; 67(9):7245-7259. PubMed ID: 38635563
[TBL] [Abstract][Full Text] [Related]
19. Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles.
Aleem S; Georghiou G; Kleiner RE; Guja K; Craddock BP; Lyczek A; Chan AI; Garcia-Diaz M; Miller WT; Liu DR; Seeliger MA
Cell Chem Biol; 2016 Sep; 23(9):1103-1112. PubMed ID: 27593110
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
